Improved anti activity of tepotinib plus gefitinib in patients with EGFR-mutant NSCLC and MET amplification was suggested [11], and limited efficacy of capmatinib in previously treated patients in advanced NSCLC with MET amplification was observed [12]. Here, MET is linked to non-small cell lung carcinoma.